Toll-Like Receptor ( TLR ) and Nucleosome-binding Oligomerization Domain ( NOD ) gene polymorphisms and endometrial cancer risk

Table 1 Genotype frequencies of polymorphisms in NOD1, NOD2, TLR2, TLR4 and TLR9 and endometrial cancer risk

Polymorphism	Genotypes	Cases n (%)	Controls n (%)	χ²	OR (95% CI) and p value
	TT	119 (62.3)	176 (60.5)
NOD1 (rs2075822)	TC	62 (32.5)	105 (36.1)		1.188
	CC	10 (5.2)	10 (3.4)	p = 0.497	(0.774-1.823) p = 0.432
	TC+CC	72 (37.7)	115 (39.5)
	AA	104 (54.5)	152 (52.2)
NOD1 (rs2907749)	AG	68 (35.6)	118 (40.6)		1.156
	GG	19 (9.9)	21 (7.2)	p = 0.392	(0.759-1.761) p = 0.499
	AG+GG	87 (45.5)	139 (47.8)
	CC	114 (59.7)	168 (57.7)
NOD1 (rs2907748)	CT	64 (33.5)	110 (37.8)		1.156
	TT	13 (6.8)	13 (4.5)	p = 0.400	(0.755-1.769) p = 0.505
	CT+TT	77 (40.3)	123 (42.3)
	CC	182 (95.3)	282 (96.9)		1.549
NOD2 (rs5743260)	CT	9 (4.7)	9 (3.1)	p = 0.359	(0.604-3.977) p = 0.363
	TT	0 (0.0)	0 (0.0)
	CC	178 (93.2)	263 (90.4)		0.928
NOD2 (rs2066844)	CT	13 (6.8)	28 (9.6)	p = 0.278	(0.407-2.116) p = 0.859
	TT	0 (0.0)	0 (0.0)
	GG	187 (97.9)	282 (96.9)		0.636
NOD2 (rs2066845)	GC	4 (2.1)	9 (3.1)	p = 0.508	(0.143-2.835) p = 0.553
	CC	0 (0.0)	0 (0.0)
	GG	177 (92.7)	275 (94.5)		1.190
TLR2 (rs5743708)	GA	14 (7.3)	16 (5.5)	p = 0.416	(0.501-2.826) p = 0.694
	AA	0 (0.0)	0 (0.0)
	AA	163 (85.3)	258 (88.7)
TLR4 (rs4986790)	AG	25 (13.1)	31 (10.6)		1.098
	GG	3 (1.6)	2 (0.7)	p = 0.449	(0.573-2.101) p = 0.778
	AG+GG	28 (14.7)	33 (11.3)
	TT	85 (44.5)	116 (39.9)
TLR9 (rs5743836)	TC	79 (41.4)	128 (44.0)		0.781
	CC	27 (14.1)	47 (16.1)	p = 0.581	(0.511-1.195) p = 0.255
	TC+CC	106 (55.5)	175 (60.1)
	TT	138 (72.25)	187 (64.3)
TLR9 (rs187084)	TC	49 (25.65)	88 (30.2)		0.675
	CC	4 (2.1)	16 (5.5)	p = 0.076	(0.428-1.064) p = 0.091
	TC+CC	53 (27.75)	104 (35.7)

NB: Χ² - Wild-type genotype versus heterozygous genotype versus homozygous variant genotype. Odds ratios for polymorphisms in NOD1, TLR4 and TLR9 were calculated as follows: Wild Type genotype compared to combination of heterozygous and homozygous variant genotypes. Odds ratios for polymorphisms in NOD2 and TLR2 were calculated as follows: Wild Type genotype compared to heterozygous genotype. All Odds Ratios were adjusted for age, BMI, diabetes, HBP, history of cancer, HT, smoking and alcohol use.